Catalyst Pharmaceuticals (CPRX) was upgraded by Zacks Research from "hold" to "strong-buy".
Catalyst Pharmaceuticals (CPRX) had its price target raised by Citigroup Inc. from $33.00 to $35.00. They now have a "buy" rating on the stock.
Catalyst Pharmaceuticals (CPRX) Reports Record Q4 and Full Year 2025 Results [Yahoo! Finance]
Is Catalyst Pharmaceuticals (CPRX) Pricing Reflect Its Strong DCF Upside After Recent Flat Returns [Yahoo! Finance]
Catalyst Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]